Villere ST Denis J & Co. LLC Has $32.55 Million Holdings in Abbott Laboratories $ABT

Key Points

• Villere ST Denis J & Co. LLC reduced its holdings in Abbott Laboratories by 2.1%, holding 239,301 shares valued at approximately $32.55 million, making it the firm's 11th largest stock investment.
• Abbott Laboratories reported a 7.4% increase in revenue year-over-year, with an EPS of $1.26 matching analysts' expectations, and set FY 2025 guidance at 5.100-5.200 EPS.
• The company announced a quarterly dividend of $0.59, providing an annualized dividend yield of 1.8%, with the payment date scheduled for November 17th.

Villere ST Denis J & Co. LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 2.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 239,301 shares of the healthcare product maker's stock after selling 5,220 shares during the quarter. Abbott Laboratories accounts for about 3.1% of Villere ST Denis J & Co. LLC's investment portfolio, making the stock its 11th largest holding. Villere ST Denis J & Co. LLC's holdings in Abbott Laboratories were worth $32,547,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Edge Financial Advisors LLC lifted its holdings in shares of Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after buying an additional 81 shares during the last quarter. Avanza Fonder AB lifted its holdings in Abbott Laboratories by 0.4% in the 2nd quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock worth $22,904,000 after purchasing an additional 655 shares during the last quarter. Madrona Financial Services LLC lifted its holdings in Abbott Laboratories by 9.7% in the 2nd quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker's stock worth $235,000 after purchasing an additional 152 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in Abbott Laboratories by 12.4% in the 2nd quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker's stock worth $91,109,000 after purchasing an additional 73,780 shares during the last quarter. Finally, SageView Advisory Group LLC lifted its holdings in Abbott Laboratories by 18.6% in the 1st quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock worth $2,427,000 after purchasing an additional 2,873 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of NYSE ABT opened at $132.30 on Friday. The business has a fifty day simple moving average of $132.54 and a 200 day simple moving average of $131.56. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $230.26 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.53 and a beta of 0.69. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.Abbott Laboratories's revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.46% of the company's stock.

Analyst Ratings Changes

ABT has been the subject of several analyst reports. Jefferies Financial Group upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their target price for the stock from $143.00 to $145.00 in a report on Friday, July 18th. BTIG Research reduced their target price on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a report on Friday, July 18th. Leerink Partners initiated coverage on Abbott Laboratories in a report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target for the company. Raymond James Financial cut their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a report on Friday, July 18th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of Abbott Laboratories in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $146.17.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.